Biotechs to use priority review voucher for cholesterol-lowering drug candidate

Regeneron Pharmaceuticals (REGN +5.8%) and partner Sanofi (SNY +1.4%) (OTCQB:SNYNF +0.3%) intend to use an FDA-issued rare pediatric disease review voucher for their alirocumab BLA. The voucher entitles the holder to designate a BLA for a six-month priority review instead of the standard 10-month review period.

Regeneron subsidiary Regeneron Ireland purchased the voucher from a subsidiary of BioMarin Pharmaceuticals who received it through the FDA's program. The companies will each pay half of the $67.5M price. They intend to submit the BLA before the end of the year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs